Research

INTRAMURALLY FUNDED PROJECTS

  1. Chemotherapy induced osteoporosis and its association with genotypes among postmenopausal breast cancer patients
  2. Role of CYFRA 21-1 and CEA as prognostic markers in locally advanced and metastatic gastric adenocarcinomas
  3. Effect of neoadjuvant treatment with zoledronic acid and chemotherapy in women with locally advanced triple negative breast cancer
  4. Evaluation of Vitamin D Supplementation in Affecting the Outcome of Newly Diagnosed Patients with Lymphoma
  5. Effect of sepsis bundle-based protocol on clinical outcomes of very high risk febrile neutropenia
  6. Study of Immune regulatory mechanisms in Acute Myeloid Leukemia (AML) with emphasis on Vitamin D mediated pathway and association with clinical outcomes
  7. Efficacy of olanzapine when added to nutritional advice in reducing anorexia in patients undergoing chemotherapy for gastric, hepato-pancreaticobiliary and lung cancer- A randomized double-blind placebo-controlled trial
  8. Study of Immune regulatory mechanisms in Acute Myeloid Leukemia (AML) with emphasis on Vitamin D mediated pathway and association with clinical outcomes
  9. Efficacy of weekly paclitaxel in combination with daily oral sodium valproate in relapsed and refractory lymphoma patients- A phase II study
  10. Predictors of chemotherapy toxicity in elderly patients
  11. Phase II Trial On Gvdexa In Relapsed Refractory Hodgkins’ Lymphoma
  12. Phase III trial of early vs. delayed treatment in biochemical relapse of myeloma

 

EXTRAMURAL PROJECTS

Name of the project PI Funding agency

1. A global, multicenter, three arms, open-label randomized study to evaluate the efficacy and safety of Nanosomal Docetaxel Lipid Suspension compared to Taxotere® (Docetaxel Injection Concentrate) in triple-negative breast cancer patients with locally advanced or metastatic breast cancer after failure to prior chemotherapy

Dr Biswajit Dubashi

INTAS pharma

2. Pattern of microbial dysbiosis in gastric cancer -A multicentric study

Dr Biswajit Dubashi

ICMR

3. Autophagy as a Target for Therapy in Ovarian Cancer: A Phase II Randomized Trial with Biomarker Correlation

Dr Prasanth Ganesan

ICMR

4. Integrated analysis of epigenetic, protein expression and metabolic mechanisms of drug resistance in relation to apoptotic pathway in acute lymphoblastic leukemia

Dr Smita Kayal

ICMR

5. Network of Oncology Clinical Trials India

Dr Prasanth Ganesan

BIRAC (National Bipharma Mission)

6. National Cancer Tissue Biobanking Project

Dr Biswajit D

Collaboration with IIT Chennai +DST, DBT

7. A prospective, multicenter, randomized, double blind, Phase III study to compare the efficacy and safety of Biosimilar Bevacizumab of Enzene Biosciences Ltd. Versus Innovator Bevacizumab both in Combination with CAPEOX in patients with Metastatic Colorectal Cancer

Dr Smita Kayal

ALKEM Pharmaceuticals

8. Predictive accuracy of change in Ki67, tumour infiltrating lymphocytes, gene expression profiling and FDG 18 PET-CT for pCR in patients with Triple negative breast cancer with single dose Paclitaxel and Carboplatin during the window period pre Neo-adjuvant chemotherapy

Dr Biswajit D

DBT

9. Post-marketing Phase 4 Study to Evaluate Safety, Tolerability, and Efficacy of Kyprolis® (Carfilzomib) in Indian Patients With Relapsed or Refractory Multiple Myeloma: A Prospective, Open-label, Non-comparative, Multicenter Study

Dr Biswajit D

 

10. Phase 4 study of daratumamab in relapsed myeloma

Dr Prasanth Ganesan

Janssen Pharma

11. Phase 4 Study of Ibrutinib in CLL and relapsed Mantle Cell Lymphoma

Dr Prasanth Ganesan

Janssen Pharma